Trials / Completed
CompletedNCT01715129
Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer
A Phase III Single Arm Study to Evaluate the Efficacy, Safety and Local Tolerability of a Subcutaneous 3-month Formulation of Triptorelin Pamoate (11.25 mg) in Patients With Locally Advanced or Metastatic Prostate Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 126 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Assess the efficacy and safety of Triptorelin pamoate 3M formulation (11.25mg) when administered by subcutaneous route.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Triptorelin Pamoate 11.25mg |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2013-10-01
- Completion
- 2013-10-01
- First posted
- 2012-10-26
- Last updated
- 2019-12-09
- Results posted
- 2015-10-28
Locations
12 sites across 5 countries: Bulgaria, France, Latvia, Poland, Romania
Source: ClinicalTrials.gov record NCT01715129. Inclusion in this directory is not an endorsement.